Stay updated on Dolutegravir Plus NRTIs in HIV-2 Clinical Trial
Sign up to get notified when there's something new on the Dolutegravir Plus NRTIs in HIV-2 Clinical Trial page.

Latest updates to the Dolutegravir Plus NRTIs in HIV-2 Clinical Trial page
- Check7 days agoChange DetectedThe update appears to be formatting/layout adjustments on the Study Details page without modifying core content (e.g., eligibility criteria, outcome measures, or study status). To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check14 days agoNo Change Detected
- Check21 days agoNo Change Detected
- Check28 days agoChange DetectedCore content updated with a government funding notice and the NIH Clinical Center operating status, plus a version bump to v3.2.0.SummaryDifference3%

- Check35 days agoChange Detected- Updated revision from v3.0.2 to v3.1.0. This indicates a new version release, but does not imply substantive changes to content visible on the page.SummaryDifference0.1%

- Check50 days agoChange DetectedVersion bump: v3.0.1 -> v3.0.2; the 'Back to Top' link was removed. No substantive changes to core content, pricing, or stock.SummaryDifference0.2%

- Check57 days agoChange DetectedThe web page has been updated from version 3.0.0 to version 3.0.1, indicating a revision in the content. There are no significant changes in core content, pricing, or availability.SummaryDifference0.2%

- Check64 days agoChange DetectedThe web page has been updated to include a new facility name and location in Lisbon, Portugal, along with a list of publications related to a clinical study on dolutegravir. Notably, previous references to certain location terms and related topics have been removed.SummaryDifference7%

Stay in the know with updates to Dolutegravir Plus NRTIs in HIV-2 Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Dolutegravir Plus NRTIs in HIV-2 Clinical Trial page.